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Application of a Physical Antimicrobial Spray Dressing for Reducing
Postoperative Peritoneal Dialysis Catheter Exit Site Infection in End-
stage Renal Failure Patients: A Prospective Cohort Study
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Objective: Exit site infection (ESI) in the early stage of peritoneal dialysis
(PD) catheter insertion period which will disrupt healthy sinus tract forma-
tion and may lead to peritonitis and catheter removal. None of the current
strategies is considered a successful measure in preventing early ESI. The
aim of this study was to evaluate the effectiveness of JUC non-pharmaco-
logical, nano-technology physical antimicrobial spray dressing (JUC) on
postoperative PD exit site care with respect to reduction of infection risk
and patient comfort.
Methods: A prospective study was conducted from December 2012 to July
2014 and the results compared with a historical cohort data obtained be-
tween 2010 to 2011 in the same Renal unit (see table). JUC was adminis-
tered to exit sites of consenting subjects. The incidence rate of ESI, the
causative microorganisms and demographic data were compared between
the study and the retrospective control group. Pain was assessed by a
numeric pain score. An exit site swab culture was performed two weeks af-
ter PD catheter insertion to determine presence of colonizing organisms.
The patients were observed for ESI for 4 weeks.
Results:Of the 95 subjects completing the study, eight developed PD catheter
ESI. ESI incidence (within 4 weeks after PD catheter insertion) in the study
groupwas only 8.4%comparedwith 19% in thecontrol group, representing a sig-
nificant decrease in ESI by 56% (PZ 0.038, Chi-squared test). The causativemi-
croorganisms for ESI in the study group were coagulase-negative Staphylococci
(12.5%), Corynebacterium species (12.5%), Staphylococcus aureus (62.5%) and
Pseudomonas aeruginosa (12.5%). For the numeric pain score (0 to 10), 93% of
the subjects reported from 0 to 2. There were no adverse effects, skin discom-
fort nor delayed sinus epithelialization for wound healing reported.
Conclusion: JUC physical non-pharmacological nano-technology antimicro-
bial spray dressing is effective and safe in preventing early postoperative PD
catheter ESI.Historical
Control
(NZ 209)
Study
Group
(NZ 95)
P value
Sex Male 122 (58.37%) 50 (52.63%) 0.66
Female 87 (41.63%) 45 (47.36%)
Age Median 60 59 0.37545
Diabetes
history
Yes 119 (56.94%) 50 (52.63%) 0.5656
No 90 (43.06%) 45 (47.37%)
Immuno-
suppressant
drug
Yes 8 (3.83%) 3 (3.16%) 0.5
No 201 (96.17%) 92 (96.84%)
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Objective: To investigate the effect of astragaloside IV (AS-IV) on the regu-
lation of the TGF-b1 Smad signaling pathway in mesothelial cells with an
epithelial-to-mesenchymal transition (EMT).
Methods: EMT of human peritoneal mesothelial cells (HMrSV5) was induced
using 2 ng/ml TGF-b1. Cells were randomly divided into a vehicle group, a
vehicle group with AS-IV, a TGF-b1 treated group, and a TGF-b1 treated
group receiving varied doses of AS-IV or NAC. Real-time quantitative PCR
and western blot were used to detect the expression of genes and proteins
associated with the TGF-b1/Smad signaling pathway and EMT. DCFH-DA was
used to detect the generation of ROS in HMrSV5 cells, and a transwell migra-
tion assay was used to verify the capacity of AS-IV to inhibit EMT in HMrSV5
cells. Lentiviruses were used as carriers for the overexpression or knock-
down of the Smad7 gene.
Results: Expression levels of E-cadherin (epithelial marker) were decreased
and vimentin, a-SMA (EMT markers) and collagen I (extracellular matrix pro-
tein) phospho-Smad2/3, Snail1 and Snail2 was increased significantly in the
TGF-b1-treated HMrSV5 cells. AS-IV was associated with downregulated
expression of vimentin and phospho-Smad2/3 in a dose-dependent manner,
while the expression of Smad7 increased. Silenced or forced expression of
Smad7 verified its role in the inhibitory effect of AS-IV on TGF-b1-induced
EMT in HMrSV5 cells.
Conclusion: AS-IV effectively promotes the upregulation of Smad7 in the
TGF-b1/Smad signaling pathway during the EMT of HMrSV5 cells, indicating
its potential therapeutic effect for the control of PF.
